Robert Tansley

Robert Tansley is a Partner at Cambridge Innovation Capital and the Chief Medical Officer at Microbiotica, based in Cambridge, United Kingdom. After completing seven years in hospital medicine with a medical degree from UCL and an MBA from London Business School, he transitioned into pharmaceutical development and regulatory roles at Sanofi and Roche. He subsequently held executive positions across the biotechnology sector, serving as the founding Chief Medical Officer at KalVista Pharmaceuticals and the Chief Executive Officer at both Treague and Avilex Pharma. In his venture capital capacity, he has managed multiple life sciences investments that resulted in successful corporate acquisitions, including the sale of Inivata to NeoGenomics, Gyroscope Therapeutics to Novartis, and PetMedix to Zoetis. His current professional focus centers on guiding early-stage therapeutics and medical technology companies from initial clinical development through commercialization.